Humanwell Healthcare Group makes a move, successfully secures new RMB 2 billion injection
On September 1, the National Medical Products Administration announced on its official website the approval of a newHuman(Rights Protection(including subsidiaries) has secured approval for two major new products in the cardiovascular and cerebrovascular systems. In 2024, the sales of Norepinephrine Bitartrate Injection exceeded 2 billion yuan in China's public medical institutions, while Icosapent Ethyl Soft Capsules surged by 963.63%. As of now, Humanwell Healthcare Group has accumulated a total of 22 chemical drugs in the cardiovascular and cerebrovascular system medication
Norepinephrine Bitartrate Injection is the top product among cardiac stimulants (excluding cardiac glycosides). In this subcategory market, Humanwell Healthcare Group Co., Ltd. previously only had oral Ephedrine Hydrochloride Tablets. The introduction of Norepinephrine Bitartrate Injection marks the group's first cardiac stimulant injectable, which holds positive
In the Chinese public medical institutions sector, which includes urban public hospitals, county-level public hospitals, urban community health centers, and township health centers, the sales of Norepinephrine Bitartrate Injection peaked at 2.25 billion yuan in 2023. Although there was a decline in 2024, sales remained above 2 billion yuan, indicating a vast market potential.
Ethyl eicosapentaenoic acid soft capsules are a potential product among other blood lipid regulators. In 2024, their growth rate in China's public medical institutions reached 963.63%, followed by a further 208.54% increase in the first quarter of 2025, making them one of the top 12 products in this subcategory market
As of now, the competitive landscape for ethyl eicosapentaenoic acid soft capsules consists of 7 domestic and 2 imported products, indicating that competition is not yet highly intense. In the list of drugs that passed the formal review for the 2025 National Reimbursement Drug List (NRDL) negotiations, announced at the end of August, ethyl eicosapentaenoic acid soft capsules met the application criteria for drugs outside the current list under condition 1/2 (new generic drugs approved for market between 2020 and June 30, 2025, with significant changes in indications or functional uses). With medical insurance supporting the take-off of new products, Humanwell Healthcare Group Co. Ltd. is expected to benefit from policy
Currently, Humanwell Healthcare Group and its subsidiaries have 22 chemical drugs in the cardiovascular system medication market, distributed across 4 subcategories (14 minor categories). In 2024, among China's public medical institutions, Humanwell's best-selling cardiovascular system medications include Metoprolol Succinate Sustained-Release Tablets, Metoprolol Tartrate Injection, Ambrisentan Tablets, and Simvastatin Capsules. With the addition of two major new products, Humanwell's competitiveness in the cardiovascular system medication market will be enhanced